JPM vs NHS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NHS presents a classic 'yield trap' scenario, characterized by a stable Piotroski F-Score of 5/9 but a critically unsustainable dividend payout ratio of 164.55%. While the stock is significantly undervalued relative to its Graham Number ($10.51) and Intrinsic Value ($10.26), the market is pricing in the risk of a dividend cut and a completely bearish technical trend (0/100). The fund maintains a stable financial health profile with low debt/equity, but the disconnect between earnings and distributions is a primary concern.
Compare Another Pair
Related Comparisons
JPM vs NHS: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Neuberger Berman Income Funds - Neuberger High Yield Strategies Fund Inc. (NHS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.